Comparing oral and intravenous ondansetron for preventing nausea in children undergoing chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of ondansetron oral soluble film combined with dexamethasone versus ondansetron administered intravenously with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in children diagnosed with solid tumors. Participants aged 6 months to 18 years will be randomly assigned to either treatment group, receiving their respective medications before and after chemotherapy. The study aims to determine which method is more effective in managing CINV during moderate to highly emetogenic chemotherapy regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Children aged 6 months to 18 years at the time of randomization;
2. Diagnosed of solid tumor by cytological or histological examination;
3. Going to initiate MEC/HEC chemotherapy;
4. PS score ≤ 2 points;
5. predicted life expectancy ≥3 months and weight greater than 6Kg;
6. Patient's parent or guardian signs informed consent

Exclusion Criteria:

1. Has vomited in the 24 hours prior to chemotherapy initiation on Treatment Day 1 ;
2. Has a symptomatic primary or metastatic central nervous system (CNS) malignancy with nausea and/or vomiting (asymptomatic participants may participate in study) ;
3. Will be receiving stem cell rescue therapy within 14 days following administration of ondansetron ;
4. Has experienced High emetic chemotherapy within two weeks ;
5. Has received or will receive total body irradiation to the abdomen or pelvis in the week prior to Treatment Day 1 and/or during the diary reporting period (120 hours following initiation of chemotherapy) ;
6. Has had benzodiazepine, opioid or opioid like therapy initiated within 48 hours prior to study drug administration, or is expected to receive within 120 hours following initiation of chemotherapy except for single doses of midazolam, temazepam or triazolam ;
7. Has started on systemic corticosteroid therapy within 72 hours prior to study drug administration or is expected to receive a corticosteroid as part of the chemotherapy regimen ;
8. Allergic to Ondansetron and dexamethasone ;
9. Has an active infection (e.g., pneumonia), congestive heart failure, bradyarrhythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy ;
10. Is mentally incapacitated or has a significant emotional or psychiatric disorder ;
11. Has a known history of QT prolongation or is taking any medication that is known to lead to QT prolongation ;
12. Abnormal liver function (alanine aminotransferase or aspartate aminotransferase ≥ 2 times higher than the upper bound of the normal value) or abnormal renal function (serum creatinine ≥ 2.5 times higher than the upper bound of the normal value) ;
13. Is currently taking, or has taken within 48 hours of Treatment Day 1 the following drugs with antiemetic properties: 5-hydroxytryptamine 3 (5-HT3) antagonists (e.g., ondansetron), benzamides (e.g., haloperidol), cyclizine, domperidone, herbal therapies with potential antiemetic properties, olanzapine, phenothiazines (e.g., prochlorperazine), scopolamine (this is not an exhaustive list) ;
14. Has ever participated in a previous study of ondansetron or has taken an investigational drug with the last 4 weeks ;
15. other situations in which the researchers believe that they cannot be included in the group.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Yizhuo Zhang — SunYat Sen University Cancer Center
• Study coordinator: Yizhuo Zhang
• Email: zhangyzh@sysucc.org.cn
• Phone: +86 87342460

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analyzing blood samples for pediatric solid tumors

  This study is trying to see if blood tests can help track how well treatment is working for kids with solid tumors by looking for cancer-related material in their blood.

  Recruiting Children's Hospital Los Angeles · Los Angeles, California · NCT05068583

• Testing CP-506 for treating advanced solid tumors

  This study is testing a new drug called CP-506 to see if it can help people with advanced solid tumors, especially those with specific DNA repair issues, by trying it alone and with other treatments.

  Recruiting at 2 sites Phase 1/2 Maastricht University Medical Center · Brussels and 4 other locations · NCT04954599

• Personalized treatment for advanced solid tumors using tumor genetics and expression profiling

  This study tests whether a patient’s tumor genetics and gene expression can guide personalized treatment choices for adults with advanced solid tumors.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT02290522

• Using genomic profiling to recommend cancer treatment for patients with metastatic tumors

  This study tests if analyzing the DNA of metastatic tumors can help doctors recommend better treatments for cancer patients.

  Recruiting Stanford University · Palo Alto, California · NCT02215928

• Registry of older patients with cancer

  This study collects health information from older cancer patients to create a registry that helps improve care and research for seniors with cancer.

  Recruiting at 7 sites UNC Lineberger Comprehensive Cancer Center · Boone, North Carolina and 6 other locations · NCT01137825

• Collecting tissue samples from cancer patients and healthy participants

  This study is collecting tissue samples from cancer patients receiving radiation therapy and healthy individuals to see how genetic differences affect treatment outcomes and to build a resource for future research.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT00992303

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.